Latest Asx Listing Rules News

PARKD Limited has completed the first tranche of its $0.78 million placement, issuing over 20 million shares at 3 cents each, while launching a Share Purchase Plan for existing shareholders.

Lord Resources has completed a $814,000 placement by issuing 22 million shares, reinforcing its funding position as it advances exploration at the Ilgarari Copper Project in Western Australia.

Myer Holdings has clarified that its FY2025 earnings aligned with market forecasts, addressing concerns following a sharp share price drop after its results announcement.

Invex Therapeutics reveals the collapse of confidential acquisition negotiations following shareholder unrest and potential board changes, clarifying recent unusual trading activity.

Hydrix Limited delays its FY25 financial statements due to a pending independent valuation of its Wavewise Analytics shareholding, triggering an automatic trading suspension from 1 October 2025.

Tungsten Mining NL has successfully raised $9.5 million through a share placement to advance its Mt Mulgine gold-tungsten project, reinforcing its position in the global tungsten market.

Anteris Technologies has gained shareholder approval for an ASX waiver allowing flexible capital raising and updated its PARADIGM trial timeline, now set to begin patient enrolment in Q4 2025 after addressing FDA requests.

Southern Palladium has responded to an ASX price query denying undisclosed information behind its recent share price rise, instead pointing to positive commodity price trends and ongoing project developments.

Bio-Gene Technology Limited has addressed ASX concerns over the timing of its announcement on promising Flavocide efficacy data, confirming compliance with continuous disclosure rules after receiving final presentation materials from Purdue University.

OncoSil Medical has affirmed the materiality of the PANCOSIL Phase 1-2 trial results and detailed its compliance with ASX disclosure rules following the data presentation at CIRSE 2025.

Invictus Energy has responded to an ASX inquiry about unusual trading activity, clarifying that recent price and volume changes followed a disclosed deferral of a placement tied to a strategic joint venture.

Uscom Limited’s shares have been suspended from trading on the ASX due to concerns over its financial health, following a critical auditor’s disclaimer. The suspension will remain until the company meets regulatory requirements.